Oncology On The Go

In this episode of Oncology On the Go , CancerNetwork® spoke with Kim Stravers, an International End-of-Life Doula Association (INELDA)–certified end-of-life doula, educator, and trainer based in the Phoenix Valley, to explore how death doulas support patients with cancer and their families across all stages of the disease trajectory. Stravers opened by defining the scope of end-of-life doula work...

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission. Once considered a terminal diagnosis, chronic myeloid leukemia (CML) in chronic phase has been fundamentally rewritten as a highly manageable chronic condition. In this episode of Oncology on the Go , Joshua Zeidner, MD, and Jorge E. Cortes, MD, s...

In this episode of Oncology On the Go, CancerNetwork® joined Matthew Matasar, MD, chief of the Division of Blood Disorders at Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medical School, as he dove into the practice-changing data reshaping the management of aggressive and indolent B-cell lymphomas. Fresh off the presentat...

In a special edition of Oncology On the Go, Chinmay Jani, MD, joined CancerNetwork® in the studio to speak about different research initiatives he is involved with across precision oncology. He discussed ongoing work dedicated to validating and applying artificial intelligence (AI)–based tools in clinical work as well as overcoming immunotherapy resistance among patients with lung cancer. Jani, ch...

Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment...

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up cl...

In a conversation with CancerNetwork®, Nathan Goodyear, MD , spoke about the role that exercise and lifestyle intervention can play in the treatment of patients with cancer. He described how prescribed exercise may serve as a biologically interventional therapy that can help prolong longevity, reduce the risk of recurrence; and supplement the efficacy of standard therapeutic approaches like chemot...

In a recent interview with CancerNetwork®, Nicholas Hornstein, MD, PhD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health, discussed emerging data and clinical shifts in the care of patients with gastrointestinal (GI) cancers ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting . Advancements in Colorectal...

In a cobranded episode between Oncology on the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the im...

Results from the first-in-human, phase 1 MYTHIC trial (NCT04855656) demonstrated that combining the WEE1 inhibitor zedoresertib with the PYKMT1 inhibitor lunresertib achieved an overall response rate (ORR) of 18.5% via RECIST criteria in patients with CCNE1 , FBXW7 , and PPP2R1A -altered cancers.1 In patients with resistant/refractory ovarian cancer, the ORR was 33.3% across all dose levels and 50...

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Barry Paul, MD, spoke with CancerNetwork® about high-level takeaways that emerged during the meeting. They discussed how CAR T-cell therapies, bispecific antibodies, and other novel modalities currently fit into the treatment paradigm across multiple myeloma, leukemia, lymp...

In a conversation with CancerNetwork®, Diane Simeone, MD, discussed the implications of daraxonrasib demonstrating meaningful improvements in survival among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the phase 3 RASolute 302 trial (NCT06625320). Topline findings from the trial showed that the novel multiselective RAS(ON) inhibitor approximately doubled the median overall s...

In a special cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of CAR T-cell–re...

At the 3rd Biennial Miami Precision Medicine Conference, CancerNetwork® spoke with a variety of researchers and clinicians who presented on different topics regarding the use of targeted therapies across several cancer types. Faculty from the University of Miami Sylvester Comprehensive Cancer Center shared key advances and ongoing initiatives across pancreatic cancer, sarcomas, genitourinary malig...

In a conversation with CancerNetwork®, Shari Goldfarb, MD spoke about key developments and challenges regarding the treatment of younger populations with breast cancer. Key areas across the field included the rising incidence of disease, including HER2-positive and triple-negative subtypes; expanding opportunities for clinical trial enrollment; and preserving fertility among patients undergoing tr...

In this episode recorded at the 2026 American Psychosocial Oncology Society (APOS) annual meeting, Daniel C. McFarland, DO, sat down with Kelly Irwin, MD, to address one of the most challenging topics in oncology: suicide risk. The conversation aimed to equip oncologists with the tools and confidence to navigate the emotional complexities of cancer care. Key Discussion Points: Understanding the Ri...

In a conversation with CancerNetwork®, Julian Hong, MD, MS, discussed considerations for optimizing care among patients with mental health disorders (MHDs) who are undergoing treatment for cancer. He spoke in the context of a study he and coauthors published in Cancer, which showed that patients with cancer and a mental health condition experience an increased risk of all-cause mortality. Specific...

In this episode of Oncology on The Go , created in collaboration with the American Psychosocial Oncology Society, Daniel C. McFarland, DO, and Ilana M. Braun, MD, dove into the complexities of cannabis use within the oncology landscape. They explored the tension between rising public popularity and the need for rigorous scientific scrutiny in symptom management. Key Discussion Points: The 2024 ASC...

During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends and developments in their respective fields. These conversations explored novel therapeutic approaches and translational research that may advance the paradigm across different leukemia, multiple myeloma, and lymphoma populations. First, Nicole Lamanna, M...

In a conversation with CancerNetwork®, Sagar Lonial, MD, FACP, FASCO, discussed the potential implications of the FDA approving iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma. He spoke in context of the FDA accepting a new drug application for the iberdomide regimen based on data from the phase 3 EXCALIBER-RRMM trial (NCT04975997). L...

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlighted the need for oncologists to recognize and address depression for patients with cancer.  In a new episode of Oncology on the Go created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, spoke with Boris Kiselev, MD. Together, they explored the complex intersection of oncology and psychiatry. Th...

Sarah Poland, MD, lead author of a recently published article in the journal ONCOLOGY titled Advances in Immunotherapy for Breast Cancer , highlighted key findings from her review in a conversation with CancerNetwork®.1 Throughout the discussion, she spoke about:  Shifting Perspectives on Immunogenicity : Historically, breast cancer was considered a “cold,” poorly immunogenic tumor due to low tumo...

At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types. First, Ferna...

In a conversation with CancerNetwork®, Manoj Bhasin, PhD, MS, spoke about findings from a study in which he and colleagues developed a single-cell atlas characterizing the dysregulation of the bone marrow immune microenvironment in newly diagnosed multiple myeloma. Findings published in Nature Cancer showed that the immune system has a broad, treatment-independent influence on outcomes in newly di...

In a conversation with CancerNetwork®, Ram Prakash Thirugnanasambandam, MBBS, discussed the evolving roles that artificial intelligence (AI)–based tools may play in palliative care and the management of different hematologic malignancies. He spoke in the context of a publication he authored, The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies, which w...